Published 2012 | Version v1
Publication

Preliminary safety results of an Italian early-access program (EAP) with cabazitaxel plus prednisone (CbzP) in patients with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC)

Additional details

Created:
April 14, 2023
Modified:
November 30, 2023